Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.30 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19211020 | 0.84 | DYRK1A (0.35) | DYRK1ADDR1MKNK1ROCK2ROCK1 | |
| SCHEMBL29444538 | 0.78 | TSHR (0.42) | ROCK2ROCK1 | |
| SCHEMBL5337466 | 0.71 | DYRK1A (0.39) | DYRK1AMKNK1ROCK2ROCK1HSP90AA1 | |
| SCHEMBL3118472 | 0.71 | DYRK1A (0.39) | DYRK1AMKNK1ROCK2ROCK1HSP90AA1 | |
| SCHEMBL3117779 | 0.71 | DYRK1A (0.39) | DYRK1AMKNK1ROCK2ROCK1HSP90AA1 | |
| SCHEMBL4520172 | 0.68 | ALDH1A1 (0.50) | CDK2 | |
| SCHEMBL23530790 | 0.67 | ALDH1A1 (0.44) | DYRK1AMKNK1ROCK2ROCK1HSP90AA1 | |
| SCHEMBL4145140 | 0.67 | KDM4E (0.44) | DYRK1AMKNK1ROCK2ROCK1HSP90AA1 | |
| SCHEMBL3105087 | 0.67 | DYRK1A (0.36) | DYRK1AHSP90AA1IDO1CDK2 | |
| SCHEMBL4520168 | 0.64 | HDAC6 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803822-B2 | Triazole derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-28 | — | — | US | disclosed |
| US-20090105253-A1 | Triazole Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1867331-A1 | TRIAZOLE DERIVATIVE AND THE USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105253-A1 | Triazole Derivative and Use Thereof | F2R, HRH4, F2RL3 | DYRK1A 1440/4885DDR1 600/4885MKNK1 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.